Scrip
02 December 2009
Sukaina Virji
sukaina.virji@informa.com
Addex Pharmaceuticals of Switzerland and Merck & Co have extended by a year the research stage of their collaboration to develop a treatment for Parkinson's disease and other indications.
The collaboration is focused on developing positive allosteric modulators (PAM) of the metabotropic...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck Serono expands multiple sclerosis research collaboration with Bionomics
- Sustained release Aricept and eribulin key near-term R&D projects for Eisai
- Boehringer Ingelheim selects Ablynx's nanobody for Alzheimer's disease
- Addex terminates development of lead drug candidate for long-term migraine and GORD therapy
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
